Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

Supplemental Table 1. Characteristics of Patients In Study vs Not in Study

Characteristics	In Study N=378	Not in Study N=356	Deceased the time of survey N=64	P[*]
Characteristics at the time of the surgery				
Age (years), mean (SD)	64.2 (9.2)	63.5 (10.0)	73.1 (10.7)	0.09
BMI (kg/m^2), median (IQR)	32.7 (27.6, 38.4)	34.6 (28.4, 41.2)	31.3 (27.5, 36.9)	0.005
BMI (kg/m^2), N (%)				0.02
<25.0	49/376 (13.0)	40/352 (11.4)	10 (15.6)	
25.0-29.9	90/376 (23.9)	67/352 (19.0)	20 (31.3)	
30.0-39.9	164/376 (43.6)	142/352 (40.3)	23 (35.9)	
40.0 or higher	73/376 (19.4)	103/352 (29.3)	11 (17.2)	
Comorbidities, N (%)				
Diabetes	59 (15.6)	66 (18.5)	20 (31.3)	0.29
CHF	8 (2.1)	2 (0.6)	4 (6.3)	0.11
Moderate/severe renal disease	5 (1.3)	7 (2.0)	5 (7.8)	0.49
Surgical details				
FIGO grade, N (%)				<0.001
1 or 2	272 (72.0)	274 (77.0)	27 (42.2)	
3	106 (28.0)	82 (23.0)	37 (57.8)	
FIGO stage, N (%)				0.31
I/II	346 (91.5)	318 (89.3)	39 (60.9)	
III/IV	32 (8.5)	38 (10.7)	25 (39.1)	
Histology, N (%)[†]				0.96
Non-endometrioid	60 (15.9)	56 (15.7)	26 (40.6)	
Endometrioid	318 (84.1)	300 (84.3)	38 (59.4)	
Study cohort, N (%)[‡]				0.30
LND cohort	251 (66.4)	249 (69.9)	50 (78.1)	
SLN cohort	127 (33.6)	107 (30.1)	14 (21.9)	
Total nodes removed via SLN among those with nodes removed, median (IQR)	3 (2, 4)	3 (2, 4)	3 (1, 3)	0.50
LND performed, n (%)				0.02
No	107 (28.3)	87 (24.4)	13 (20.3)	
Pelvic only	162 (42.9)	189 (53.1)	22 (34.4)	
Paraaortic only	3 (0.8)	5 (1.4)	-	
Pelvic and paraaortic	106 (28.0)	75 (21.1)	29 (45.3)	
Total nodes removed via LND among those with nodes removed, median (IQR)				
Total pelvic and paraaortic	29 (21, 40)	27 (18, 38)	25 (19, 37)	0.07
Total pelvic	24 (17, 33)	24 (17, 32)	20 (12, 28)	0.66
Total paraaortic	13 (9, 19)	13 (9, 20)	10 (8, 15)	0.90
Total nodes removed by any means (SLN+ LND), median (IQR)	24 (6, 36)	21 (7, 34)	22 (9, 30)	0.70
Adjuvant EBRT, N (%)				0.43
No	345 (91.3)	315 (88.5)	45 (70.3)	
Yes	18 (4.8)	24 (6.7)	10 (15.6)	
Unknown	15 (4.0)	17 (4.8)	9 (14.1)	

Abbreviations: BMI, body mass index; CHF, congestive heart failure; EBRT, external beam radiation therapy; FIGO, International Federation of Gynecology and Obstetrics; IQR, interquartile range; LND, lymphadenectomy; SD, standard deviation SLN, sentinel lymph node.

[*]Comparison between "In Study" and "Not in Study" only; two-sample t test P value presented for age, Wilcoxon rank sum test P values presented for all other continuous variables, and chi-square or Fisher's exact test P values presented for categorical variables.

[†]Endometrioid histology includes endometrioid and mixed endometrioid and mucinous histology; non-endometrioid histology includes serous, clear cell, carcinosarcoma, undifferentiated, mixed serous, mixed clear cell, and mixed undifferentiated histology.

[‡]The LND cohort consists of patients who underwent bilateral LND prior to SLN implementation at our institution or as "backup" after SLN mapping and the SLN cohort consists of patients who underwent a SLN biopsy with or without side-specific LND.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

Supplemental Table 2. Characteristics of Patients Stratified by Method of Nodal Sampling

Characteristic	LND cohort*	SLN cohort*	HYST only cohort	LND cohort vs HYST only cohort $P^\dagger$	SLN cohort vs HYST only cohort $P^\dagger$
	N=251	N=127	N=165		
Characteristics at the time of the surgery					
Age (years), mean (SD)	64.2 (9.1)	64.1 (9.4)	62.1 (10.7)	0.004	0.02
BMI (kg/m^2), median (IQR)	32.2 (27.1, 37.7)	33.4 (28.6, 40.0)	32.7 (26.8, 40.9)	0.38	0.37
BMI (kg/m^2), N (%)				0.005	0.02
<25.0	39/249 (15.7)	10 (7.9)	31/162 (19.1)		
25.0-29.9	57/249 (22.9)	33 (26.0)	33/162 (20.4)		
30.0-39.9	112/249 (45.0)	52 (40.9)	51/162 (31.5)		
40.0 or higher	41/249 (16.5)	32 (25.2)	47/162 (29.0)		
Comorbidities, N (%)					
Diabetes	41 (16.3)	18 (14.2)	33 (20.0)	0.34	0.19
CHF	2 (0.8)	6 (4.7)	1 (0.6)	0.99	0.046
Moderate/severe renal disease	3 (1.2)	2 (1.6)	3 (1.8)	0.69	0.99
Surgical details					
FIGO grade, N (%)				<0.001	<0.001
1 or 2	171 (68.1)	101 (79.5	159 (96.4)		
3	80 (31.9)	26 (20.5)	6 (3.6)		
FIGO stage, N (%)				0.01	0.18
I/II	227 (90.4)	119 (93.7)	160 (97.0)		
III/IV	24 (9.6)	8 (6.3)	5 (3.0)		
Histology, N (%) [‡]				<0.001	<0.001
Non-endometrioid	43 (17.1)	17 (13.4)	3 (1.8)		
Endometrioid	208 (82.9)	110 (86.6)	162 (98.2)		
Adjuvant EBRT, N (%)				0.03	0.31
No	227 (90.4)	118 (92.9)	157 (95.2)		
Yes	14 (5.6)	4 (3.1)	1 (0.6)		
Unknown	10 (4.0)	5 (3.9)	7 (4.2)		

Abbreviations: BMI, body mass index; CHF, congestive heart failure; EBRT, external beam radiation therapy; FIGO, International Federation of Gynecology and Obstetrics; HYST, hysterectomy; IQR, interquartile range; LND, lymphadenectomy; SD, standard deviation SLN, sentinel lymph node.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

*The LND cohort consists of patients who underwent bilateral LND prior to SLN implementation at our institution or as "backup" after SLN mapping and the SLN cohort consists of patients who underwent a SLN biopsy with or without side-specific LND.

†Two-sample t-test P value presented for age, Wilcoxon rank-sum test P values presented for all other continuous variables, and chi-square or Fisher's exact test P values presented for categorical variables.

‡Endometrioid histology includes endometrioid and mixed endometrioid and mucinous histology; non-endometrioid histology includes serous, clear cell, carcinosarcoma, mixed serous, and mixed clear cell histology.